News coverage about Aratana Therapeutics (NASDAQ:PETX) has been trending somewhat positive this week, Accern reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Aratana Therapeutics earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.3666613394223 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Aratana Therapeutics (NASDAQ:PETX) opened at 6.23 on Tuesday. The firm’s 50-day moving average price is $5.88 and its 200-day moving average price is $6.17. The stock’s market cap is $267.90 million. Aratana Therapeutics has a 12 month low of $4.97 and a 12 month high of $10.73.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.29) by $0.03. The business had revenue of $5.16 million for the quarter, compared to analyst estimates of $4.50 million. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The company’s quarterly revenue was down 86.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.61 EPS. On average, analysts predict that Aratana Therapeutics will post ($1.09) earnings per share for the current year.

A number of equities analysts have issued reports on the company. Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, July 13th. ValuEngine upgraded Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. BidaskClub downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Jefferies Group LLC set a $8.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 4th. Finally, Lake Street Capital lowered their price target on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Friday, August 25th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $8.25.

COPYRIGHT VIOLATION WARNING: This article was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.thecerbatgem.com/2017/09/19/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-aratana-therapeutics-petx-stock-price.html.

Aratana Therapeutics Company Profile

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Stock Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related stocks with our FREE daily email newsletter.